long intergenic non-protein coding RNA 1923Genealiases: []
Q-omics provides the consensus-scored LINC01923 profile across patient tissues and cancer cell-line models. LINC01923 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, LINC01923 is differentially expressed in 2, with the highest sampling consensus in COAD. Additionally, LINC01923 RNA expression shows 6,862 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight COAD, and STAD as cancer lineages where LINC01923 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01923 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01923 survival associations across molecular data types. LINC01923 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01923 RNA expression–survival associations across cancer types. High LINC01923 expression shows unfavorable associations in KICH, UVM, ACC, DLBC and KIRC, but favorable associations in COAD. The COAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for LINC01923 RNA expression.
This table summarizes LINC01923 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01923. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01923 shows lower tumor expression in COAD and READ. The COAD box plot shows higher LINC01923 RNA expression in normal versus tumor tissue (log2 FC = −0.148, t-test p = .006).
This table shows molecular features associated with LINC01923 in patient tissues and cancer cell lines. In patient samples, LINC01923 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
